Advancing Therapies from Bench to Bedside
L

ast year, DIA continued to provide a unique forum for advancing the field of translational science by collaborating and exchanging fresh insights with health authorities, industry, regulators, patients, and academics.

  • Together with the National Center for Advancing Translational Sciences (NIH-NCATS) we convened a group of industry clinical development experts to provide input into NCATS’ Trial Innovation Network.
  • Together with the National Center for Advancing Translational Sciences (NIH-NCATS) we convened a group of industry clinical development experts to provide input into NCATS’ Trial Innovation Network.
  • Our active DIA Clinical Trial Disclosure Community addressed questions related to the implementation of recent Clinical Trial Disclosure guidelines, including the EMA Policy 0070 and the US Final Rule.
  • We convened a Rare Diseases Town Hall at our 2017 Global Annual Meeting to address challenges specific to orphan drug development, and published a White Paper in the American Heart Journal that examines methods to collect social listening data for use in cardiac safety surveillance.
  • We explored ways to accelerate the translation of basic research to clinical application in China at the 3rd DIA China Drug Discovery Innovation Conference.
  • The 14th DIA Japan Annual Meeting focused on advancing the field of genomic medicine and the development of next-generation medicines through big data and artificial intelligence.
  • Our active DIA Clinical Trial Disclosure Community addressed questions related to the implementation of recent Clinical Trial Disclosure guidelines, including the EMA Policy 0070 and the US Final Rule.
  • We convened a Rare Diseases Town Hall at our 2017 Global Annual Meeting to address challenges specific to orphan drug development, and published a White Paper in the American Heart Journal that examines methods to collect social listening data for use in cardiac safety surveillance.
  • We explored ways to accelerate the translation of basic research to clinical application in China at the 3rd DIA China Drug Discovery Innovation Conference.
  • The 14th DIA Japan Annual Meeting focused on advancing the field of genomic medicine and the development of next-generation medicines through big data and artificial intelligence.
3rd China Drug Discovery Innovation Conference, Suzhou

Why we care: Translational science turns laboratory, clinical, and community findings into interventions that improve the health of individuals and the public. DIA works closely with researchers at the forefront of this rapidly advancing field to break through roadblocks and accelerate therapies from bench to bedside.

For an overview of translational science themed articles published by DIA, listen to these podcasts featuring Drs. Gary Kelloff and David Parkinson.

We have a history of fostering dialogue among government granting agencies and other players in the translational science space, including TransCelerate Biopharma Inc. and the Clinical Trials Transformation Initiative (CTTI). In 2017, we engaged industry clinical development experts to provide feedback on NCATS’ Trial Innovation Network, a national multidisciplinary network focused on tackling common roadblocks in clinical trial research through operational innovation and collaboration.

As the field of translational science evolved rapidly, we worked with experts in the field to keep you up to date on the latest advances in oligonucleotide-based therapeutics, gene and stem cell therapy, immuno-oncology, organs-on-chips, and regenerative medicine. Our members contributed their knowledge and expertise to numerous publications and podcasts, drawing you into lively discussions on numerous topics, including:

  • The use of real word evidence to complement clinical trials
  • Best practices to address CMC (Chemistry, Manufacturing, and Control) challenges in the development of oligo-based therapies
  • Applications of CRIPSR-Cas9 technology to treat diseases
  • The potential of wearables and other technologies to advance affordable precision medicine
  • The identification and use of disease state biomarkers
  • Advances in rare disease clinical research

Award winners, 14th DIA Japan Annual Meeting 2017.

We also dedicated two important DIA meetings to current advances in translational science: the 3rd China Drug Discovery Innovation Conference and the 14th DIA Japan Annual Meeting. Aptly themed “Translational Medicine – Building a Bridge from Bench to Bedside,” our meeting in China responded to the country’s rapid advancements in the drug R&D sphere and the strong support for innovation in the wake of China’s recent sweeping regulatory reform. The meeting provided a platform for three days of in-depth discussion on early-stage research innovation and design, translation of early-stage R&D results into licensed drugs, market authorization, and other advances in translational medicine. In Japan, we were honored to feature as keynote speaker Japan’s 2016 Nobel Laureate in Physiology and Medicine, Professor Yoshinori Ohsumi, whose human cell research made a lasting impact on genomic medicine. Focused on advancing genomic medicine and product development via AI and big data, the meeting explored the future of next-generation ICT (Information and Communication Technology) in drug development and timely drug delivery.

Participants share ideas in a special chat session, 14th DIA Japan Annual Meeting 2017